Skip to main content
. 2025 Jun 20;312(3):909–918. doi: 10.1007/s00404-025-08085-5

Table 5.

Treatment-emergent adverse events and adverse drug reactions in the analysis population

n (%) IDA
(n = 114)
IDNA
(n = 205)
Overall
(n = 319)
Patients with TEAEs 27 (23.7) 49 (23.9) 76 (23.8)
  Grade 3 2 (1.0) 2 (0.6)
Patients with ADRs 6 (5.3) 16 (7.8) 22 (6.9)
  Grade 3 2 (1.0) 2 (0.6)

ADR adverse drug reaction, IDA iron deficiency anemia, IDNA iron deficiency without anemia, TEAE treatment-emergent adverse event